Patents Assigned to AbbVie Inc.
  • Publication number: 20240232171
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 22, 2024
    Publication date: July 11, 2024
    Applicant: ABBVIE INC.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
  • Publication number: 20240180901
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 6, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak SAMPATH, Christian KLEIN, Wayne John FAIRBROTHER
  • Patent number: 11993606
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: May 28, 2024
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Aileen L. Pangan, In-Ho Song, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Patent number: 11993605
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: May 28, 2024
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Patent number: 11993613
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 28, 2024
    Assignee: AbbVie Inc.
    Inventors: Puneet Kumar, Anthony Mastracchio, Mark Mills, Andrew William Phillips
  • Publication number: 20240158368
    Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 16, 2024
    Applicant: AbbVie Inc.
    Inventors: David A. Degoey, Michael R. Schrimpf, David J. Hardee, Jacob Ludwig, Eric R. Miller, Timothy R. Hodges, Alberto Munoz, Sarah J. Perlmutter, Huan-Qiu X. Li, Alvin Jang, Elizabeth L. Noey, Gregory A. Gfesser, Edgars Jecs, Robert G. Schmidt, Justin D. Dietrich, Xenia B. Searle, Boguslaw P. Nocek, Andrew Bogdan
  • Patent number: 11976077
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: May 7, 2024
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Patent number: 11964990
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: April 23, 2024
    Assignee: AbbVie Inc.
    Inventors: George A. Doherty, Vikram Bhat, Andrew S. Judd, Andrew J. Souers
  • Publication number: 20240115650
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 11, 2024
    Applicant: ABBVIE INC.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Publication number: 20240108616
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: November 10, 2023
    Publication date: April 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: 11939320
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 26, 2024
    Assignee: AbbVie Inc.
    Inventors: Jennifer M. Frost, Lei Shi, Yunsong Tong, Michael J. Dart, Kathleen J. Murauski
  • Publication number: 20240091248
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 21, 2024
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • Publication number: 20240075026
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: February 8, 2023
    Publication date: March 7, 2024
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Patent number: 11897672
    Abstract: A blank of sheet material for forming a sleeve container, the blank of sheet material including two side panels each including a bottom edge and a top edge, and two elongated side panels arranged alternatingly with the side panels. A plurality of fold lines are defined between the side panels and the elongated side panels, and the elongated side panels include a side panel portion and a guide flap extending beyond the top edge of the side panels. The side panels and the side panel portions are configured to define an interior cavity of the sleeve container, and the guide flaps are configured to define an insertion guide channel that is in communication with the interior cavity.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: February 13, 2024
    Assignee: ABBVIE INC.
    Inventors: Guy C. Upchurch, James J. Hughes, Jovo Dragicevic
  • Patent number: 11897864
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: February 13, 2024
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20240043404
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: September 6, 2023
    Publication date: February 8, 2024
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20240011884
    Abstract: Systems and methods for inspecting particles in a liquid beneficial agent are provided.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 11, 2024
    Applicant: ABBVIE INC.
    Inventors: Edmund Matayoshi, Sheng Tu, Jie Wang
  • Publication number: 20240000776
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: D1007142
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: December 12, 2023
    Assignee: ABBVIE INC.
    Inventors: Robert Malick, Jennifer Cudworth, Melissa Terrill, Michael Rakauskas, Kyle Neuser, Miranda Degg, Corin Frost, Maddie Gibson
  • Patent number: D1034191
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: July 9, 2024
    Assignee: AbbVie Inc.
    Inventors: Todd Marshall, Marc Plew, Ted Klikuszowian, Joy Elizabeth Borgardt, James Hughes, Kelsey M. Coffey, Scott L. Fisher, Jason A. Rowe